Vedolizumab: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Vedolizumab. Educational only — not medical advice.

Labeled uses

ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD).

Source: FDA labeling via NIH DailyMed (set 6e94621c…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.